Full-Time

Automation Engineer

Clear Labs

Clear Labs

51-200 employees

Clinical diagnostics via whole genome sequencing

Compensation Overview

$120.5k - $151.8k/yr

+ Stock Option Plan

San Carlos, CA, USA

In Person

Category
Biology & Biotech (1)

Get referred to Clear Labs

See people who can refer or advise you

Requirements
  • At least 8 years of hands-on experience programming and developing methods on Hamilton STAR/STAR2 or directly equivalent liquid-handling platforms, including VENUS software, deck layout design, and liquid class development.
  • Hands-on experience troubleshooting Hamilton hardware and peripherals, including pipetting channels, iSWAP/gripper mechanisms, heater-shakers, plate sealers, and third-party integrated modules.
  • Experience maintaining and validating a multi-unit automation fleet, including qualifying individual instruments rather than relying on representative sampling.
  • Ability to independently script and modify automated methods in a regulated environment with full change-control documentation.
  • Statistical fluency sufficient to independently evaluate automated performance against validation acceptance criteria.
  • Preference for hands-on bench and deck work rather than a delegate-only role.
Responsibilities
  • Contribute hands-on reliability engineering, method development, and troubleshooting expertise for the Hamilton STAR/STAR2 liquid-handling automation fleet running next-generation sequencing library preparation workflows.
  • Help design and execute formal automated-versus-manual equivalence and validation studies for next-generation sequencing sample preparation in support of regulatory requirements.
  • Support root-cause investigations for automation performance issues affecting next-generation sequencing library quality and sequencing output by systematically evaluating mechanical, calibration, and liquid-class variables, and flag labware-related findings to Systems Integration for formal qualification.
  • Partner with Regulatory and Quality on validation protocols and documentation for a regulated, FDA-cleared diagnostics workflow.
  • Collaborate on vendor and equipment relationships as needed to support fleet performance.
Desired Qualifications
  • Working knowledge of next-generation sequencing library preparation workflows, such as hybrid capture and/or amplicon-based enrichment, as executed on automated liquid handling.
  • Understanding of how automation method parameters, including liquid class, tip type, mixing, and incubation, affect next-generation sequencing library yield, uniformity, and sequencing quality-control metrics.
  • Experience troubleshooting automation-driven failures that manifest downstream in sequencing data, such as low on-target rate, coverage dropout, and well-position-specific effects.
  • Prior oncology diagnostics experience, including next-generation sequencing-based companion diagnostics or comprehensive genomic profiling workflows.

Clear Labs delivers diagnostic solutions for healthcare and food safety using whole genome sequencing (WGS) and next-generation sequencing (NGS) to detect infectious disease outbreaks and to test food for safety. Its flagship Clear Dx Microbial Surveillance WGS provides an automated end-to-end sequencing system for bacterial and fungal isolates. It also offers SARS-CoV-2 surveillance and wastewater monitoring to expand its surveillance services and markets. Its goal is to enable faster, more accurate detection and monitoring of infectious diseases and foodborne pathogens to protect public health and support business growth.

Company Size

51-200

Company Stage

Series D

Total Funding

$150.2M

Headquarters

San Carlos, California

Founded

2014

Get referred to Clear Labs

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • March 2026 Labcorp partnership targets streamlined oncology NGS workflows.
  • July 2026 rebranding clarifies Clear Ix infectious-disease products and reduces customer confusion.
  • The 2025 $30 million Series D still funds commercialization and assay expansion.

What critics are saying

  • Revelio Labs counted 83 employees in March 2026, down 12.6% since 2023.
  • Only two 2026 job postings signal a thin sales and regulatory execution bench.
  • A failed oncology pivot traps the company below scale and starves future financing.

What makes Clear Labs unique

  • Clear Labs automates sample-to-answer NGS workflows, cutting manual steps across diagnostics.
  • Its 2026 Clear Dx oncology platform extends automation beyond infectious disease RUO.
  • Labcorp collaboration and Clear Ix rebrand show one platform spanning research and clinical workflows.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours

Meal Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Employee Assistance Program

Stock Options

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

3%

2 year growth

1%
PR Newswire
Jun 4th, 2025
Clear Labs Launches New Fully Automated Ngs Platform For Rapid Bacterial And Fungal Detection From Sterile Site Specimens

"Our goal is to bring high-confidence microbial identification into more laboratories by eliminating the technical and logistical barriers to sequencing." — Sasan Amini, CEO, Clear Labs

FinSMEs
Jan 13th, 2025
Clear Labs Raises $30M in Series D Financing

Clear Labs raises $30M in Series D financing.

Kilmer Lucas
Jan 13th, 2025
Clear Labs secures $30M, adds Keegan

Clear Labs completed a $30 million series D financing round to enhance its sequencing solutions, led by a strategic investor with participation from existing investors like Counterpoint Global and Khosla Ventures. The funding will support growth, innovative assays, and expansion of its Clear Dx platform. Kevin Keegan joins the board of directors. CEO Dr. Sasan Amini emphasized the impact on NGS technology and healthcare outcomes.

AgFunder
Sep 28th, 2023
Bytes To Bites Part Two – From Farm To Fork: Leveraging Ai In The Food Supply Chain

Editor’s Note: Eva Everloo is senior investment analyst, and Anina Troya is an investment analyst intern at agri-food tech investor PeakBridge.The views expressed in this guest commentary are the authors’ own and do not necessarily reflect those of AgFunderNews.From accelerated drug discovery and turbo-charged R&D, to sparkling marketing copy and improved customer service, artificial intelligence (AI) and machine learning (ML) are being deployed in every field. But what do they bring to the food industry?In the second segment of a three-part deep dive into AI in food, Peakbridge explores the potential of AI to address food safety, transparency and quality challenges across the food supply chain.The contemporary globalized food value chainIn today’s world, the global food value chain is like a complex puzzle that spans the planet, enabling the distribution of vital sustenance. This system involves numerous stakeholders, including farmers, manufacturers, distributors, retailers, and consumers, all interconnected in a delicate balance. In the 2020s, the world witnessed the disruption of this intricate network with the COVID-19 pandemic.Another more recent example is the Avian Flu outbreak in the United States, which resulted in economic costs ranging from US$2.5 billion to US$3 billion, foodshortages and exacerbated food prices. Imagine artificial intelligence (AI) and blockchain decentralized tracking networks had been in place to collect infectious disease data transparently and reliably and to forecast supply and demand with an optimized food network distribution.Climate change is another challenge that impacts the entire food value chain, revealing its vulnerabilities. It has caused erratic crop yields, resulting in manufacturing shortages, increased transportation costs, and pricing fluctuations

PR Newswire
May 22nd, 2023
Clear Labs Launches Microbial Surveillance Whole Genome Sequencing Solution

SAN CARLOS, Calif. (PRWEB). May 22, 2023. Clear Labs, a leader in next-generation sequencing automation workflow solutions, announces the launch of the Clear Dx™ Microbial Surveillance WGS, a fully-automated, end-to-end whole genome sequencing (WGS) solution for bacterial and fungal isolates. This groundbreaking application sets a new standard for speed, efficiency and simplicity in pathogen characterization